Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

NCT02601313 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Mantle Cell Lymphoma

Interventions

BIOLOGICAL: brexucabtagene autoleucel
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Axicabtagene Ciloleucel

Sponsor

Kite, A Gilead Company